Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed Non-Hodgkin-Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT01460134
What this trial is testing

CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers

Who this might be right for
CD27 Expressing B-cell Malignancies for Example Hodgkin's LymphomaChronic Lymphocytic LeukemiaMantle Cell Lymphoma+7 more
Celldex Therapeutics 90
Large-scale testing (Phase 3)Study completedNCT01938001
What this trial is testing

Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)

Who this might be right for
Lymphoma, Non-Hodgkin
Celgene 358
Testing effectiveness (Phase 2)Ended earlyNCT03547700
What this trial is testing

Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)

Who this might be right for
Lymphoma, T-Cell, Peripheral
University of Michigan Rogel Cancer Center 11
Testing effectiveness (Phase 2)UnknownNCT03156101
What this trial is testing

A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in R/R ALL and Lymphoma Subjects

Who this might be right for
Relapsed B-cell Acute Lymphoblastic LeukemiaRefractory B-cell Acute Lymphoblastic LeukemiaRelapsed／Refractory B-cell Lymphoma
Shenzhen BinDeBio Ltd. 24
Early research (Phase 1)Study completedNCT00012207
What this trial is testing

Biological Therapy After Chemotherapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Who this might be right for
LeukemiaLymphoma
Fred Hutchinson Cancer Center 12
Testing effectiveness (Phase 2)Study completedNCT00448357
What this trial is testing

Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaLymphoma+2 more
UNC Lineberger Comprehensive Cancer Center 54
Early research (Phase 1)Study completedNCT03236857
What this trial is testing

The Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies

Who this might be right for
MalignanciesAcute Lymphoblastic Leukemia (ALL)Acute Myeloid Leukemia (AML)+2 more
AbbVie 143
Early research (Phase 1)Looking for participantsNCT05054257
What this trial is testing

CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma

Who this might be right for
Relapsed or Refractory B-cell Acute Lymphoblastic LeukemiaNon-Hodgkin's Lymphoma RefractoryNon-Hodgkin's Lymphoma, Relapsed
Institute of Hematology and Blood Transfusion, Czech Republic 10
Early research (Phase 1)Study completedNCT05950334
What this trial is testing

FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)

Who this might be right for
Relapsed/Refractory B-Cell Lymphoma
Fate Therapeutics 20
Large-scale testing (Phase 3)Study completedNCT04182204
What this trial is testing

Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche 270
Testing effectiveness (Phase 2)Study completedNCT03456726
What this trial is testing

Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation

Who this might be right for
Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Eisai Co., Ltd. 20
Testing effectiveness (Phase 2)Study completedNCT02939014
What this trial is testing

Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)

Who this might be right for
Hodgkin DiseaseLymphoma, Large-Cell, Anaplastic
Takeda 39
Testing effectiveness (Phase 2)Looking for participantsNCT07042438
What this trial is testing

Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells

Who this might be right for
Recurrent Diffuse Large B-Cell LymphomaRecurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRecurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma+3 more
City of Hope Medical Center
Testing effectiveness (Phase 2)Study completedNCT00295932
What this trial is testing

Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

Who this might be right for
LeukemiaLymphoma
Memorial Sloan Kettering Cancer Center 79
Testing effectiveness (Phase 2)Study completedNCT00076349
What this trial is testing

SDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL)

Who this might be right for
Non-Hodgkin's Lymphoma
Cephalon 66
Early research (Phase 1)Study completedNCT04067414
What this trial is testing

Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma

Who this might be right for
Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaTransformed Lymphoma+1 more
Institute of Hematology & Blood Diseases Hospital, China 12
Testing effectiveness (Phase 2)Study completedNCT00901147
What this trial is testing

Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma

Who this might be right for
Peripheral T-cell Lymphoma (Not Otherwise Specified)Angioimmunoblastic T-cell LymphomaExtranodal NK/T-cell Lymphoma Nasal Type+4 more
Singapore General Hospital 25
Testing effectiveness (Phase 2)Study completedNCT01660451
What this trial is testing

Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas

Who this might be right for
Lymphoma, Non-Hodgkin
Bayer 227
Early research (Phase 1)Ended earlyNCT04045028
What this trial is testing

Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Who this might be right for
Multiple MyelomaNon-Hodgkin LymphomaB-Cell Lymphoma
Genentech, Inc. 41
Not applicableUnknownNCT04109872
What this trial is testing

Lenalidomide Observational Study in Patients With Mantle Lymphoma in Relapse/Refraction. Spanish Programme RRMCL Results.

Who this might be right for
Mantle Cell Lymphoma
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla 25
Next Page
56